{"nctId":"NCT00531427","briefTitle":"Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee","startDateStruct":{"date":"2007-09"},"conditions":["Chronic Pain","Osteoarthritis of the Knee"],"count":567,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Buprenorphine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* subjects with moderate to severe chronic osteoarthritis (OA) pain of the knee (lasting several hours daily) as their predominant pain condition,\n* clinical diagnosis of OA of the knee 1 year or longer,\n* subjects treated within the 14 days prior to screening with nonopioid therapy only, or with therapy including opioids at a dose of \\< 5 mg oxycodone (or equivalent) per day,\n* subjects whose OA knee pain is not adequately controlled with nonopioid analgesic medication and who the investigator feels are appropriate candidates for around-the-clock opioid therapy.\n\nExclusion Criteria:\n\n* subjects who have had arthroscopy on either knee or hip within 6 months of entering the study or open surgery on either knee or hip within 9 months of entering the study,\n* subjects who are allergic to buprenorphine or who have a history of allergies to other opioids,\n* subjects who have allergies or other contraindications to transdermal delivery systems or patch adhesives.\n\nOther protocol-specific inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"\"Average Pain Over the Last 24 Hours\" Score of the Study Knee at Week 12 of the Double Blind Phase.","description":"\"Average pain over the last 24 hours\" scores of the study knee at week 12 was evaluated on an 11-point scale: 0 = no pain, 10 = worst pain imaginable, recorded daily.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.16","spread":"1.340"},{"groupId":"OG001","value":"7.06","spread":"1.300"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.63","spread":"1.292"},{"groupId":"OG001","value":"2.74","spread":"1.186"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.82","spread":"2.644"},{"groupId":"OG001","value":"4.22","spread":"2.644"}]}]}]},{"type":"SECONDARY","title":"Mean Daily Number of Tablets of Nonopioid Supplemental Analgesic Used From Week 2 to 12 of the Double-blind Phase.","description":"Subjects were permitted to take sponsor-provided supplemental analgesic medication after week 1 of the double-blind treatment (acetaminophen or ibuprofen).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.701","spread":"0.8139"},{"groupId":"OG001","value":"0.740","spread":"0.8566"}]}]}]},{"type":"SECONDARY","title":"Sleep Disturbance Subscale of the MOS-Sleep Scale at Weeks 4, 8, and 12 of the Double-blind Phase.","description":"The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of sleep and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete. Question 1 is scored on a scale of 1 to 5 ( 1 = 0-15 min to more than 60 min) and Questions 2 to 12 are scored on a scale of 1 to 6 (1 = all of the time to 6 = none of the time. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7, and 8 and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.51","spread":"24.790"},{"groupId":"OG001","value":"51.23","spread":"25.945"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.23","spread":"19.583"},{"groupId":"OG001","value":"26.04","spread":"20.822"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.22","spread":"23.086"},{"groupId":"OG001","value":"35.08","spread":"25.565"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.46","spread":"23.795"},{"groupId":"OG001","value":"34.78","spread":"24.715"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.60","spread":"25.177"},{"groupId":"OG001","value":"33.63","spread":"25.606"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":282},"commonTop":["Nausea","Application site pruritus","Dizziness","Somnolence","Headache"]}}}